Kamada Ltd (IL:KMDA)
NASDAQ:KMDA
Want to see IL:KMDA full AI Analyst Report?
KMDA Stock Chart & Stats
2502.00
1.39(5.72%)
At close: 4:00 PM EST
2502.00
1.39(5.72%)
Day’s Range― - ―
52-Week Range1,899.20 - 2,806.07
Previous CloseN/A
Volume698.59K
Average Volume (3M)61.53K
Market Cap
₪1.28B
Enterprise Value429.25M
Total Cash (Recent Filing)₪73.15M
Total Debt (Recent Filing)₪11.64M
Price to Earnings (P/E)22.6
Beta0.72
Next Earnings
Aug 19, 2026EPS Estimate
31.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.35
Shares Outstanding57,686,054
10 Day Avg. Volume102,707
30 Day Avg. Volume61,533
Financial Highlights & Ratios
PEG Ratio0.41
Price to Book (P/B)1.52
Price to Sales (P/S)2.09
P/FCF Ratio24.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₪3,669.16Price Target Upside46.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.44
Revenue Forecast (FY)₪202.22M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthKamada's very low leverage and sizable equity base provide durable financial flexibility: supports ongoing capex for plasma centers, funds dividends and potential M&A, and reduces refinancing risk during cyclical revenue swings, enabling steadier execution of strategic growth plans.
Long-term Commercial ContractsA multi-year Kedrion supply deal with minimums through 2031 gives sustained revenue visibility and production planning certainty. This underpins capacity utilization, reduces commercial volatility, and materially de-risks near-term organic growth assumptions embedded in guidance.
Vertical Integration & Plasma ExpansionOwning FDA-approved plasma centers creates secure raw material sourcing and lowers COGS risk over time. Normal-source plasma sales and planned capacity improve supply resilience, enhance gross margin upside potential and support long-term self-sufficiency for plasma-derived therapeutics.
Bears Say
Cash Flow VolatilityFree cash flow has been inconsistent: TTM FCF covered only ~61% of net income and prior years included negative FCF. This uneven conversion constrains capital allocation flexibility, raises sensitivity to revenue timing, and could pressure dividend sustainability or fund investment without external financing.
Margin PressureA ~5 percentage‑point Y/Y gross margin decline reflects product and geographic mix shifts. If structural mix, pricing or reimbursement trends persist, margin compression would reduce adjusted EBITDA and free cash flow, weakening the company’s ability to fund growth initiatives and sustain dividend targets.
Revenue Variability / SeasonalityDependence on end‑user patterns, partner inventory cadence and outbreak-driven demand creates quarter-to-quarter revenue swings. Such variability complicates capacity planning and forecasting, can magnify cash flow volatility and makes consistent margin expansion harder to achieve over the medium term.
Kamada News
KMDA FAQ
What was Kamada Ltd’s price range in the past 12 months?
Kamada Ltd lowest stock price was 1899.20 and its highest was 2806.07 in the past 12 months.
What is Kamada Ltd’s market cap?
Kamada Ltd’s market cap is ₪1.28B.
When is Kamada Ltd’s upcoming earnings report date?
Kamada Ltd’s upcoming earnings report date is Aug 19, 2026 which is in 80 days.
How were Kamada Ltd’s earnings last quarter?
Kamada Ltd released its earnings results on May 13, 2026. The company reported 23.87 earnings per share for the quarter, missing the consensus estimate of 32.68 by -8.809.
Is Kamada Ltd overvalued?
According to Wall Street analysts Kamada Ltd’s price is currently Undervalued.
Does Kamada Ltd pay dividends?
Kamada Ltd pays a Notavailable dividend of 71.008 which represents an annual dividend yield of N/A. See more information on Kamada Ltd dividends here
What is Kamada Ltd’s EPS estimate?
Kamada Ltd’s EPS estimate is 31.83.
How many shares outstanding does Kamada Ltd have?
Kamada Ltd has 57,686,054 shares outstanding.
What happened to Kamada Ltd’s price movement after its last earnings report?
Kamada Ltd reported an EPS of 23.87 in its last earnings report, missing expectations of 32.68. Following the earnings report the stock price went down -7.347%.
Which hedge fund is a major shareholder of Kamada Ltd?
Currently, no hedge funds are holding shares in IL:KMDA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kamada Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
₪3,669.16 (46.65% Upside)
₪3,669.16 (46.65% Upside)
Blogger Sentiment
Bullish
IL:KMDA Sentiment 100%
Sector Average ―
Sector Average ―
Technicals
SMA
Positive
20 days / 200 days
Momentum
19.70%
12-Months-Change
Fundamentals
Return on Equity
7.73%
Trailing 12-Months
Asset Growth
2.11%
Trailing 12-Months
Company Description
Kamada Ltd
Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis ; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
KMDA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call balanced clear operational progress and strategic catalysts—reaffirmed 2026 guidance, FDA approval of a plasma center, expanding commercial and distribution initiatives, growing utilization of key products, and a maintained dividend—with near‑term headwinds including a shipment delay, gross margin compression, and slight cash reduction following the dividend. Management emphasized organic growth drivers and M&A/business development opportunities, and adjusted EBITDA and net income trends were stable to modestly improved, supporting a constructive outlook despite some quarter‑specific challenges.View all IL:KMDA earnings summariesKMDA Stock 12 Month Forecast
Average Price Target
3,669.16
▲(46.65% Upside)